Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study
Qing-Zhu Zhao1, Bao-Cheng Liu, Jing Zhang
1Bio-X Institute, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, People's Republic of China.
Psychiatric Genetics
|September 1, 2012
Summary
This study found a specific COMT gene variation (rs9606186) is linked to better risperidone treatment response in Chinese schizophrenia patients, particularly males. This genetic marker may predict antipsychotic medication efficiency.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Psychiatry
Background:
- Schizophrenia is influenced by genetic factors, including the catechol-O-methyl transferase (COMT) gene.
- COMT gene polymorphisms are implicated in both schizophrenia susceptibility and individual responses to antipsychotic medications.
- Understanding these genetic influences can optimize treatment strategies for schizophrenia.
Purpose of the Study:
- To investigate the association between COMT gene single-nucleotide polymorphisms (SNPs) and the efficacy of risperidone monotherapy in a Chinese population with schizophrenia.
- To explore potential sex-specific differences in the genetic influence of COMT on risperidone response.
Main Methods:
- Genotyping of 10 COMT SNPs in 130 Chinese schizophrenia patients.
- Assessment of clinical efficacy using Brief Psychiatric Rating Scale (BPRS) scores after 8 weeks of risperidone treatment.
- Statistical analysis to identify associations between COMT SNPs and BPRS score reduction.
Main Results:
- A significant association was found between the COMT SNP rs9606186 and reduced BPRS scores in the overall patient group and the male subgroup.
- This association was not significant in the female subgroup, indicating a potential sexually dimorphic effect.
- Allele and genotype analyses showed statistically significant results for rs9606186 in all patients and males (uncorrected P-values).
Conclusions:
- The COMT gene polymorphism rs9606186 is associated with risperidone treatment efficiency in Chinese schizophrenia patients.
- A sexually dimorphic difference in this association was observed, suggesting sex-dependent mechanisms of COMT in antipsychotic response.
- These findings may contribute to personalized medicine approaches in schizophrenia treatment based on genetic profiles.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...